Bispecific ANXA2/CD147 CAR-T cell therapy for osteosarcoma
Targeting two cancer proteins simultaneously with CAR-T cells addresses why single-target approaches fail, offering hope for solid tumors like osteosarcoma.
Bispecific ANXA2/CD147-targeting CAR-T cells demonstrate preclinical efficacy against osteosarcoma with dual-antigen targeting addressing the antigen-loss escape mechanism that limits single-target CAR-T in solid tumors. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- experimental_preclinical
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Oncogene
Why it surfaced
Novel bispecific CAR-T for osteosarcoma, a pediatric bone malignancy with critical unmet need at relapse and very few approved targeted options; dual-antigen strategy addresses fundamental solid tumor CAR-T limitation; Oncogene publication; translational intent indicated by multidisciplinary author team.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.